Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stanford University Study Shows Early Detection of CTCs in NSCLC Patients

Published: Tuesday, November 26, 2013
Last Updated: Tuesday, November 26, 2013
Bookmark and Share
IsoFlux System demonstrates high sensitivity CTC recovery in challenging patient group.

Fluxion Biosciences, Inc. has announced the presentation of the first pilot study results aimed at isolating circulating tumor cells (CTCs) from early stage non-small cell lung cancer (NSCLC) patients obtained in collaboration with Dr. Max Diehn’s lab at Stanford University.

CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body. They circulate in very low concentration in the peripheral blood and are not readily retrievable with conventional technologies.

The IsoFlux System recovers these rare tumor cells from a standard blood draw and prepares them for molecular analysis. The platform offers improved sensitivity of CTC recovery in a low-volume format optimized for analytical platforms.

The results, presented at the American Society for Radiation Oncology (ASTRO) 2013 Annual Meeting, compared CTC counts in healthy controls, early stage, and advanced stage NSCLC patients. Mean pre-treatment CTC counts were 1.7, 28.4, and 142.4, respectively.

Cell count differences were statistically significant between controls and early stage patients (p = 0.01). No controls had greater than 5 CTCs while 73% of early stage patients did. Gross tumor volume was shown to positively correlate with CTC count (p=0.04).

"This data is very exciting and validates the high sensitivity CTC recovery technology that the IsoFlux System was built around. The platform enables the use of molecular profiling tools earlier in the disease progression and without invasive procedures,” said Cristian Ionescu-Zanetti, Fluxion’s Chief Technology Officer.

Customers have adopted the system to isolate and characterize CTCs for biomarkers including gene expression, mutations (qPCR and next generation sequencing), and chromosomal aberrations.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fluxion Biosciences, UT Health Collaborate
Company has announced collaboration with UT Health to develop novel liquid biopsy approaches to improve the ability to diagnose, monitor, and treat cancer patients.
Saturday, April 30, 2016
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Senor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Investigating ‘Black Box’ of Human Genetics
Investigations into inactive X chromosomes have shown unusual DNA repeat elements are essential for maintaining 3D structure.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!